title: Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.
abstract: Severe Impairment Battery (SIB) data from the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study suggest that patients with severe Alzheimer's disease (AD) benefit from treatment with 13.3 versus 4.6 mg/24 h rivastigmine patch. The objective of this retrospective analysis was to further examine the cognitive efficacy of 13.3 versus 4.6 mg/24 h rivastigmine patch on individual SIB items, and SIB domains derived using factor analysis of these items. Change from baseline at Week 24 on 9 new factor-defined domains and individual items was calculated and compared using effect sizes (Cohen's d). Numerically less decline was observed with 13.3 versus 4.6 mg/24 h patch on all domains and the majority of individual items. Largest least squares mean treatment differences were observed on "visuospatial reasoning," "object naming," "recognition," "design copying," "social agency," "ideational praxis," and "comprehension" domains. These findings suggest 13.3 mg/24 h rivastigmine patch demonstrates broad cognitive efficacy across a range of SIB items and domains in patients with severe AD.
authors.affiliation: Department of Neurology, Weill Cornell Medical College, New York, NY, USA rii9004@med.cornell.edu.
authors.forename: Richard S
authors.initials: RS
authors.lastname: Isaacson
authors.affiliation: Center for Cognitive Neurology, Alzheimer's Disease Center, NYU Langone Medical Center, New York, NY, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Ferris
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Drew M
authors.initials: DM
authors.lastname: Velting
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
authors.forename: Xiangyi
authors.initials: X
authors.lastname: Meng
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D012189:Retrospective Studies; D000068836:Rivastigmine / Q000008:administration & dosage / Q000494:pharmacology*; D012720:Severity of Illness Index; D057968:Transdermal Patch
chemical_list: D002800:Cholinesterase Inhibitors; D000068836:Rivastigmine
keywords: Severe Impairment Battery; cholinesterase inhibitor; cognition; randomized clinical trial; rivastigmine patch; severe Alzheimer’s disease